Introduction. Among the most common congenital coagulopathies are haemophilia and Von Willebrand disease. These illnesses are often mimicked by orphan hereditary coagulopathies, including combined coagulation factor V and VIII deficiency.Aim — description of a clinical presentation, hampered diagnosis and choice of haemostatic therapy in a surgical patient with combined blood coagulation factor V and VIII deficiency.Main findings. We describe a clinical case of congenital combined factor V and VIII deficiency and detail the aetiology, frequency, localisation and intensity of haemorrhages. Comorbidity and surgical indications are demonstrated to require an inter-specialty medical involvement.
6 July 2022 in Russian journal of hematology and transfusiology
Introduction. In most cases, in patients with hereditary fibrinogen deficiency, clinical manifestations are represented by bleeding of varying intensity and localization. However, the clinical picture of hereditary fibrinogen deficiency can also be represented by thrombosis.Aim — to characterize the detected mutations in fibrinogen genes and to analyze prothrombotic factors in patients with hereditary hypofibrinogenemia and thrombosis.Materials and methods. Forty-nine patients with hereditary hypofibrinogenemia were observed, of which 46 patients had no history of thrombosis and 3 patients had a confirmed history of thrombosis. These 3 patients made up the study group.Results. Heterozygous mutations were found in all 3 patients in the fibrinogen gamma chain gene (FGG), one of them had a previously undescribed deletion g.2653_2684+211del, p.(Asp167Glufs*2), which removes 32 terminal nucleotides of the fifth exon of the FGG gene and leads to the formation of a stop codon in place of amino acid 168. In two other patients, there were missense mutations c.1140T>A, p.(Cys365Ser) and c.1114A>T, p.(Asp356Val), which can determine the thrombogenic properties of the altered protein structure of fibrinogen. Other prothrombotic factors were also identified: genetic polymorphisms of low thrombotic risk, surgery, taking combined oral contraceptives.Conclusion. Hereditary fibrinogen deficiency does not play a protective role in relation to the development of thrombosis and may cause the development of thrombosis, which is associated with its multifunctional role in the hemostasis system. The pathogenesis of thrombosis in patients with hereditary hypofibrinogenemia is multifactorial and may be associated with the characteristics of the main protein defect and the coexistence of hereditary and acquired thrombotic risk factors (surgical interventions, taking combined oral contraceptives, etc.).
In “bilineal” mixed-phenotype acute leukemia (MPAL), the proportions of lymphoid and myeloid leukemic cells may differ substantially. A myeloid component may constitute <10% of bone marrow (BM) cells and show subtle immunophenotypic abnormalities detectable by multicolor flow cytometry (MFC). The significance of minor myeloid leukemic populations in otherwise acute lymphoblastic leukemia (ALL), including their association with lineage switch, remains uncertain. We retrospectively reviewed diagnostic MFC data from 5094 children with B-cell precursor or T-cell ALL. An additional minor myeloid leukemic population (<10% of BM) was identified in 92 ALL cases (1.8%), with a median of 3.0% of BM cells (0.2–9.2%). The frequency of ALL cases harboring a minor myeloid leukemic population was comparable to that of overt “bilineal” MPAL (with both populations ≥ 10% of BM cells), diagnosed during the same period. The myeloid populations expressed CD33, CD64, CD14, lysozyme, and markers shared with the dominant lymphoblastic population (CD19/CD7, CD34, CD117). Common genetic findings were high hyperdiploidy (n = 14), KMT2A rearrangements (n = 13), and BCR::ABL1 (n = 8). Although no expansion was documented in most patients, 6 of 83 newly diagnosed patients (7.2%) developed lineage switch to acute myeloid leukemia or overt “bilineal” MPAL. Most cases were managed successfully with standard ALL-directed therapy.